In this video, Mark T. Fleming, MD, discusses results from the SPOTLIGHT study, which he presented at this year’s American Urological Association meeting.
“It’s very exciting that we’re having a potential modality that really is able to find prostate cancer recurrence better than the conventional imaging that is out there,” Fleming, physician with Virginia Oncology Associates and national policy board chair for The US Oncology Network, said.
In this video, Mark T. Fleming, MD, discusses results from the SPOTLIGHT study, which he presented at this year’s American Urological Association meeting.
“It’s very exciting that we’re having a potential modality that really is able to find prostate cancer recurrence better than the conventional imaging that is out there,” Fleming, physician with Virginia Oncology Associates and national policy board chair for The US Oncology Network, said.
